Logo image of ESLA

ESTRELLA IMMUNOPHARMA INC (ESLA) Stock Fundamental Analysis

USA - NASDAQ:ESLA - US2975841048 - Common Stock

2.33 USD
+0.46 (+24.6%)
Last: 10/22/2025, 8:00:02 PM
2.41 USD
+0.08 (+3.43%)
After Hours: 10/22/2025, 8:00:02 PM
Fundamental Rating

2

Overall ESLA gets a fundamental rating of 2 out of 10. We evaluated ESLA against 534 industry peers in the Biotechnology industry. While ESLA seems to be doing ok healthwise, there are quite some concerns on its profitability. ESLA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ESLA has reported negative net income.
In the past year ESLA had a positive cash flow from operations.
ESLA had negative earnings in each of the past 5 years.
In the past 5 years ESLA always reported negative operating cash flow.
ESLA Yearly Net Income VS EBIT VS OCF VS FCFESLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of ESLA (-405.17%) is worse than 95.32% of its industry peers.
Industry RankSector Rank
ROA -405.17%
ROE N/A
ROIC N/A
ROA(3y)-188.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ESLA Yearly ROA, ROE, ROICESLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ESLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ESLA Yearly Profit, Operating, Gross MarginsESLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, ESLA has more shares outstanding
There is no outstanding debt for ESLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ESLA Yearly Shares OutstandingESLA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
ESLA Yearly Total Debt VS Total AssetsESLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

ESLA has an Altman-Z score of -26.68. This is a bad value and indicates that ESLA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -26.68, ESLA is doing worse than 87.83% of the companies in the same industry.
ESLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Altman-Z -26.68
ROIC/WACCN/A
WACCN/A
ESLA Yearly LT Debt VS Equity VS FCFESLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

ESLA has a Current Ratio of 0.16. This is a bad value and indicates that ESLA is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.16, ESLA is doing worse than 96.07% of the companies in the same industry.
A Quick Ratio of 0.16 indicates that ESLA may have some problems paying its short term obligations.
The Quick ratio of ESLA (0.16) is worse than 95.88% of its industry peers.
Industry RankSector Rank
Current Ratio 0.16
Quick Ratio 0.16
ESLA Yearly Current Assets VS Current LiabilitesESLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M 8M

More info and screens

1

3. Growth

3.1 Past

ESLA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 82.64%, which is quite impressive.
EPS 1Y (TTM)82.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-49.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 77.03% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-132.85%
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%
EPS Next 5Y77.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ESLA Yearly Revenue VS EstimatesESLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
ESLA Yearly EPS VS EstimatesESLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ESLA. In the last year negative earnings were reported.
Also next year ESLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ESLA Price Earnings VS Forward Price EarningsESLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ESLA is valued cheaper than 99.63% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.15
EV/EBITDA N/A
ESLA Per share dataESLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A cheap valuation may be justified as ESLA's earnings are expected to decrease with -67.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%

More info and screens

0

5. Dividend

5.1 Amount

ESLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ESTRELLA IMMUNOPHARMA INC

NASDAQ:ESLA (10/22/2025, 8:00:02 PM)

After market: 2.41 +0.08 (+3.43%)

2.33

+0.46 (+24.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12
Earnings (Next)N/A N/A
Inst Owners1.71%
Inst Owner Change0%
Ins Owners2.16%
Ins Owner Change0%
Market Cap86.37M
Revenue(TTM)N/A
Net Income(TTM)-12076200
Analysts82.86
Price Target16.32 (600.43%)
Short Float %0.33%
Short Ratio1.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF 7.15
P/OCF 7.15
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.33
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)0.33
FCFY13.98%
OCF(TTM)0.33
OCFY13.98%
SpS0
BVpS-0.16
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -405.17%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.16
Quick Ratio 0.16
Altman-Z -26.68
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-49.71%
EPS Next Y-132.85%
EPS Next 2Y-90.91%
EPS Next 3Y-67.6%
EPS Next 5Y77.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-65.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1159.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1159.11%
OCF growth 3YN/A
OCF growth 5YN/A